Giorgia Migliardi

Turin, Italy

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 23 publications

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Author Correction: The genomic landscape of response to EGFR blockade in colorectal cancer.

Journal: Nature

Published: February 16, 2026

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Phosphoproteomics of patient-derived xenografts identifies targets and markers associated with sensitivity and resistance to EGFR blockade in colorectal cancer.

Journal: Science translational medicine

Published: August 16, 2023

Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.

Case report: Preclinical efficacy of NEDD8 and proteasome inhibitors in patient-derived models of signet ring high-grade mucinous colorectal cancer from a Lynch syndrome patient.

Journal: Frontiers in oncology

Published: December 23, 2022

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.

Molecular Subtyping Combined with Biological Pathway Analyses to Study Regorafenib Response in Clinically Relevant Mouse Models of Colorectal Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: March 12, 2021

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Colorectal cancer residual disease at maximal response to EGFR blockade displays a druggable Paneth cell-like phenotype.

Journal: Science translational medicine

Published: April 26, 2019

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models.

Journal: Journal of experimental & clinical cancer research : CR

Published: March 06, 2019

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Prioritization of cancer therapeutic targets using CRISPR-Cas9 screens.

Journal: Nature

Published: August 03, 2018

Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin.

Vigilance on use of drugs, herbal products, and food supplements during pregnancy: focus on fosfomycin.

Journal: The journal of maternal-fetal & neonatal medicine : the official journal of the European Association of Perinatal Medicine, the Federation of Asia and Oceania Perinatal Societies, the International Society of Perinatal Obstetricians

Published: September 05, 2017

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.

C-met inhibition blocks bone metastasis development induced by renal cancer stem cells.

Journal: Oncotarget

Published: May 01, 2016

Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.

Efficacy of NEDD8 Pathway Inhibition in Preclinical Models of Poorly Differentiated, Clinically Aggressive Colorectal Cancer.

Journal: Journal of the National Cancer Institute

Published: February 25, 2016

HER2 activating mutations are targets for colorectal cancer treatment.

HER2 activating mutations are targets for colorectal cancer treatment.

Journal: Cancer discovery

Published: August 06, 2015

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Lenalidomide normalizes tumor vessels in colorectal cancer improving chemotherapy activity.

Journal: Journal of translational medicine

Published: July 09, 2015

Showing 1-12 of 23

Last Updated: 09/26/2026